LONDON, July 13, 2022 (GLOBE NEWSWIRE) -- The “HER2+ Breast Cancer – Global Drug Forecast and Market Analysis to 2030” report offered by GlobalData provides opportunities for various marketed agents and pipeline agents in development across the 8MM, clinical and commercial assessments for agents in late-stage clinical development, R&D strategies, and innovative approaches in development for HER2+ breast cancer.
The sales of HER2+ breast cancer therapies in the 8MM were estimated at $10.4 billion in 2020 and is expected to increase at a CAGR of more than 1% during the forecast period. Global sales are dominated by the US due to its large patient population and higher cost of therapy in the country.
To get comprehensive statistics on HER2+ breast cancer drugs market sizing and forecast, download a sample report
HER2+ Breast Cancer Drugs Market Drivers
- Approval and launch of premium-priced therapeutics in the 8MM during the forecast period: two small molecule inhibitors, two antibody-drug conjugates, and a checkpoint inhibitor.
- Label expansions of established drugs into earlier, more lucrative lines of therapy.
- Reformulation of established blockbusters into a branded sub-cutaneous, fixed-dose form will reduce the impact of biosimilar erosion.
- Increased disease incidence across the 8MM.
Unmet Needs and Opportunity Assessment of the HER2+ Breast Cancer Drugs Market
The unmet need in HER2+ breast cancer could be considered moderate, based on the major advancement observed in treating this disease. However significant unmet needs do exist. While there is still an emphasis on improved treatment options, in particular curative interventions and treatment of patients with brain metastases, there is also an emphasis on patient quality of life. Other notable unmet needs include the need to stratify patients based on their specific molecular profile and how to effectively treat intratumor heterogeneity.
For more insights on HER2+ breast cancer drugs market drivers and unmet needs, download a sample report
Leading Companies in the HER2+ Breast Cancer Market
- Roche (Genentech)
- AstraZeneca
- Daiichi Sankyo
- Pfizer
- Novartis
The current HER2+ breast cancer market is dominated by Genentech (a member of the Roche group) and the company is expected to retain its position as the market leader over the forecast period. Genentech’s success is built upon a history of effective development within the indication, originating from the hugely successful development and commercialization of Herceptin, and with the addition of Kadcyla and Perjeta to its HER2-directed franchise.
To know more about leading companies in the HER2+ breast cancer drugs market, download a sample report
HER2+ Breast Cancer Drugs Market Report Scope
- Overview of HER2+ breast cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline HER2+ market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics including the current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HER2+ therapeutics sales in the 8MM.
- Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
- Analysis of the current and future market competition in the global HER2+ market and insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global HER2+ therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2+ market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the global HER2+ therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Related Reports
- Bipolar Disorder – Global Drug Forecast and Market Analysis to 2030 – Click here
- Glaucoma – Global Drug Forecast and Market Analysis to 2030 – Click here
- Endometriosis – Global Drug Forecast and Market Analysis to 2030 – Click here
- Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
- Metastatic Melanoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update – Click here
HER2+ Breast Cancer Drugs Market Overview
| Market Size 2020 | $10.4 billion |
| CAGR | >1% |
| Forecast Period | 2021 - 2030 |
| Leading Companies | Roche (Genentech), AstraZeneca, Daiichi Sankyo, Pfizer, and Novartis |
FAQs
What was the HER2+ breast cancer market size in 2020?
The HER2+ breast cancer market size was $10.4 billion in 2020.
What is the HER2+ breast cancer market growth rate?
The HER2+ breast cancer market is projected to grow at a CAGR of more than 1% during the forecast period.
Which are the leading companies in the HER2+ breast cancer market?
Some of the leading companies in the HER2+ breast cancer market are Roche (Genentech), AstraZeneca, Daiichi Sankyo, Pfizer, and Novartis.
Table of Contents
| About GlobalData
1 HER2+ Breast Cancer: Executive Summary
1.1 The HER2+ Breast Cancer Market Will Expand to
12.1B in 2030
1.2 Roche/Genentech to Maintain its Leading Position Despite Competition from Biosimilars and Enhertu
1.3 Treatment of Brain Metastases, Intratumor Heterogeneity, and Improving Patient Outcomes Remain the Unmet Needs
1.4 Novel Antibody-Drug Conjugates and Established Breast Cancer Drugs Populate the Late-Stage Pipeline
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for All Invasive and HER2-Positive Breast Cancer (2020-2030)
4.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer
4.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer
4.5.3 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer
4.5.4 Diagnosed Incident Cases of HER2+/HR- Breast Cancer
4.5.5 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stages
4.5.6 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stages
4.5.7 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status
4.5.8 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status
4.5.9 Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression
4.5.10 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression
4.5.11 Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression
4.5.12 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis
4.5.13 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis
4.5.14 Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression
4.5.15 Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
5.2.1 Testing
5.2.2 Neoadjuvant/Adjuvant Treatment Paradigm
5.2.3 Metastatic
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improving Curative Options and Patient Outcomes
7.3 Treatment of Patients with Brain Metastases
7.4 Stratifying Patients According to Molecular Profiles and Reducing Toxicities of Existing Regimens
7.5 Treating Intratumor Heterogeneity
8 R&D Strategies
8.1 Overview
8.1.2 Development of Subcutaneous and Fixed Dose Formulations of Blockbusters
8.1.3 Label Expansions into Earlier Lines of Therapy
8.1.4 Novel Therapeutic Approaches to Treating HER2+ Breast Cancer
8.2 Clinical Trials Design
8.2.1 Preferred Primary Outcomes Measures Dependent on Line of Therapy
8.2.2 Increased Utility of Quality of Life and Patient Reported Outcome Measures
8.2.3 Assessment of Novel Biomarkers to Predict Response
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers – Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 China
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting Methodology
13.4 Primary Research – KOLs Interviewed for This Report
13.4.1 KOLs
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologist
13.6.5 Global Director of Therapy Analysis and Epidemiology
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
| Contact Us
About us
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
